SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    KUBO to build Glass Pharms UK cannabis cultivation facility

    By
    Home / KUBO to build Glass Pharms UK cannabis cultivation facility

    Recently securing up to £26.7m of funding from a FTSE-250 listed investment fund, Glass Pharms has announced a team of “best-of-breed” partners to complete its cultivation facility.

    KUBO has been selected to deliver a state-of-the-art 2.5 hectare greenhouse for the UK-based medical cannabis cultivation company Glass Pharms’ facility in the South of England.

    In order to ensure sophisticated control of climatic conditions and low energy consumption, the greenhouse will harness KUBO’s patented Ultra-Clima® system. 

    Read more: Glass Pharms hires one of UK’s most experienced glasshouse growers

    Additionally, Glass Pharms intends to make the facility carbon negative, and it will be powered entirely by renewable energy generated from food waste fed into an anaerobic digestion (AD) plant.

    Waste hot water from the AD plant will also be used for both heating and cooling, and the greenhouse will harvest and recycle rainwater – representing a new benchmark for sustainable enclosed agriculture in the UK. 

    Glass Pharms CEO, James Duckenfield, commented: “We will underpin a secure supply chain of affordable medical cannabis to UK patients without them having to compromise on freshness or quality, whilst at the same time making a real contribution towards the UK’s Net Zero targets.”

    Alongside KUBO, Askam Civil Engineering, with specific sector expertise, will also be providing the required civils and headhouse fitout for the facility.

    Glass Pharms announced it would be building the greenhouse in December 2021, when it stated that the facility will enable to company to grow medical cannabis to the correct regulatory standards for onward supply to UK pharmacies and clinics.

    Speaking at the time, Duckenfield, commented: “We will underpin a secure supply chain of medical cannabis to UK patients without them having to compromise on freshness or quality, whilst at the same time making a real contribution towards the UK’s Net Zero targets.”

    Earlier this year the company announced Richard Lewis, one of the UK’s most experienced glasshouse growers, as its managing director, and has stated it will shortly announce its plant-specific expert.

    [activecampaign form=31]

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free